Your browser doesn't support javascript.
loading
Reducción de la esteatosis hepática, insulino resistencia y pérdida de la defensa antioxidante en ratones alimentados con dieta alta en grasa suplementados con AGPICL n-3 más aceite de oliva extra virgen / Reduction of hepatic steatosis, insulin resistance and loss of antioxidant defense in high fat diet fed mice suplemented with n-3 LCPUFA more extra virgin olive oil
Valenzuela B., Rodrigo; Hernández-Rodas, María Catalina; Barrera R., Cynthia; Pérez B., Francisco; Ruz O., Manuel.
  • Valenzuela B., Rodrigo; Universidad de Chile. Facultad de Medicina. Departamento de Nutrición. CL
  • Hernández-Rodas, María Catalina; Universidad de Chile. Facultad de Medicina. Departamento de Nutrición. CL
  • Barrera R., Cynthia; Universidad de Chile. Facultad de Medicina. Departamento de Nutrición. CL
  • Pérez B., Francisco; Universidad de Chile. Facultad de Medicina. Departamento de Nutrición. CL
  • Ruz O., Manuel; Universidad de Chile. Facultad de Medicina. Departamento de Nutrición. CL
Rev. chil. endocrinol. diabetes ; 8(4): 154-161, oct. 2015. tab, ilus
Article in Spanish | LILACS | ID: biblio-831329
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is directly associated with insulin resistance and oxidative stress. In NAFLD is established a reduction in n-3 LCPUFA (EPA + DHA) levels and hepatic activity of transcription factor PPAR-alpha. EPA and DHA inhibit lipogenesis and stimulate fatty acid oxidation in the liver. Extra virgin olive oil (EVOO) has important antioxidant properties. This study evaluated the prevention of insulin resistance and prevention of depletion of hepatic antioxidant defense inC57BL/6J mice fed high-fat diet (HFD), supplemented with n-3 LCPUFA plus EVOO. HFD generated insulin resistance and hepatic steatosis, together with significant reduction in i) n-3 LCPUFA hepatic levels, ii) DNA binding activity of PPAR-alpha, iii) activity of antioxidant enzymes (catalase and superoxide dismutase), respect to control group (fed with control diet). Supplementation with n-3 LCPUFA plus EVOO prevent development insulin resistance and attenuate increased of fat in liver (p < 0.05), together with a normalization of i) DNA binding activity of PPAR-á, ii) activity of antioxidant enzymes (catalase and superoxide dismutase) and iii) reducing depletion of n-3 LCPUFA levels in liver tissue, compared to the control group (p < 0.05). Supplementation with n-3 LCPUFA plus EVOO reduced hepatic steatosis and prevent development of insulin resistance, along with preserving the antioxidant defense in liver. Projecting the use of this mixture of AGPICL n-3 plus EVOO as a potential treatment of NAFLD.
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Dietary Supplements / Diet, High-Fat / Non-alcoholic Fatty Liver Disease / Olive Oil Limits: Animals Language: Spanish Journal: Rev. chil. endocrinol. diabetes Journal subject: Endocrinology Year: 2015 Type: Article / Project document Affiliation country: Chile Institution/Affiliation country: Universidad de Chile/CL

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Dietary Supplements / Diet, High-Fat / Non-alcoholic Fatty Liver Disease / Olive Oil Limits: Animals Language: Spanish Journal: Rev. chil. endocrinol. diabetes Journal subject: Endocrinology Year: 2015 Type: Article / Project document Affiliation country: Chile Institution/Affiliation country: Universidad de Chile/CL